Memantine Hydrochloride
Product Images NDC 50090-4203

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 50090-4203). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500904203)

Memantine Hydrochloride 10 mg tablet container label from A-S Medication Solutions. It shows the product name, active ingredient strength, lot number, storage instructions (store at 60 to 77 degrees F), quantity of 90 tablets, NDC 50090-4203-0, and a dosage instruction to see the package insert. The label includes manufacturing information from Sun Pharma and barcodes for tracking.*

FDA Label Image

Spl-memantine-chemical-structure (Spl Memantine Chemical Structure)

Chemical structure of Memantine Hydrochloride showing the molecular framework with amine (NH2) and hydrochloride (HCl) groups attached to a tricyclic cage-like structure with methyl groups.*

FDA Label Image

Spl-memantine-figure1 (Spl Memantine Figure1)

A line graph comparing the mean change from baseline in ADCS-ADL score over 28 weeks of treatment between placebo and Memantine Hydrochloride groups. The Y-axis shows change in score, while the X-axis represents weeks of treatment. The graph displays clinical improvement and decline with respective data points and error bars for each group.*

FDA Label Image

Spl-memantine-figure2 (Spl Memantine Figure2)

A cumulative percentage graph comparing patients treated with Memantine Hydrochloride versus placebo over 28 weeks. The x-axis shows ADCS-ADL changes from baseline, and the y-axis shows the cumulative percentage of patients. Data indicates a higher cumulative percentage of patients with greater negative ADCS-ADL changes in the Memantine Hydrochloride group compared to placebo.*

FDA Label Image

Spl-memantine-figure3 (Spl Memantine Figure3)

A line graph comparing mean change from baseline in SIB score over 28 weeks of treatment for Placebo and Memantine Hydrochloride groups. The graph shows clinical improvement and decline thresholds, with Memantine Hydrochloride maintaining near baseline scores, while Placebo shows progressive decline.*

FDA Label Image

Spl-memantine-figure4 (Spl Memantine Figure4)

A cumulative percentage line graph comparing patients treated with Memantine Hydrochloride versus placebo over 28 weeks. The x-axis shows the SIB (Severe Impairment Battery) change from baseline, and the y-axis shows the cumulative percentage of patients. Two lines represent the treatment groups, with Memantine Hydrochloride showing a higher cumulative percentage of patients at greater negative SIB change values, indicating treatment effect over the placebo.*

FDA Label Image

Spl-memantine-figure5 (Spl Memantine Figure5)

A line graph showing the mean change from baseline in ADCS-ADL score over 24 weeks of treatment with Memantine Hydrochloride/Donepezil versus Placebo/Donepezil. The x-axis represents weeks of treatment from 0 to 24, and the y-axis shows the mean change in ADCS-ADL score. The graph highlights clinical improvement and clinical decline benchmarks, with Memantine Hydrochloride/Donepezil showing less decline over time compared to Placebo/Donepezil.*

FDA Label Image

Spl-memantine-figure6 (Spl Memantine Figure6)

A cumulative percentage line graph comparing patients completing 24 weeks of double-blind treatment with Memantine Hydrochloride/Donepezil versus Placebo/Donepezil, showing changes from baseline in ADCS-ADL scores. The x-axis represents ADCS-ADL change from baseline, and the y-axis shows cumulative percentage of patients.*

FDA Label Image

Spl-memantine-figure7 (Spl Memantine Figure7)

Line graph depicting the mean change from baseline in SIB score over 24 weeks of treatment for Memantine Hydrochloride/Donepezil versus Placebo/Donepezil. The graph shows clinical improvement and decline regions, with Memantine Hydrochloride/Donepezil showing an increase, and Placebo/Donepezil showing a decrease in SIB score over time.*

FDA Label Image

Spl-memantine-figure8 (Spl Memantine Figure8)

A cumulative percentage plot showing changes in SIB (Severe Impairment Battery) scores from baseline for patients completing 24 weeks of double-blind treatment. The graph compares placebo/donepezil group (square markers) and memantine hydrochloride/donepezil group (circle markers), illustrating patient distribution by SIB score change.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.